Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453564 | 0.87 | F10 (0.81) | F10 | |
| SCHEMBL4453563 | 0.87 | F10 (0.81) | F10 | |
| SCHEMBL4447483 | 0.86 | F10 (0.55) | F10 | |
| SCHEMBL4442285 | 0.86 | F10 (1.00) | F10 | |
| SCHEMBL4453431 | 0.84 | F10 (1.00) | F10 | |
| SCHEMBL1028206 | 0.84 | F10 (0.76) | F10 | |
| SCHEMBL1026249 | 0.84 | F10 (0.76) | F10 | |
| SCHEMBL1031000 | 0.84 | F10 (0.76) | F10 | |
| SCHEMBL5016564 | 0.84 | F10 (0.81) | F10 | |
| SCHEMBL4447412 | 0.82 | F10 (1.00) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F9, F2, F12 | F10 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.